Seek Returns

AMGN vs. GILD: Amgen vs. Gilead Sciences Stock Comparison

How do Amgen (AMGN) and Gilead Sciences (GILD) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.

Company Profile

Amgen (AMGN) and Gilead Sciences (GILD) are both classified in the Biotechnology sub-industry within the broader Biotechnology industry, placing them in the closest GICS peer bucket.

Company profile comparison for Amgen (AMGN) and Gilead Sciences (GILD)
Profile ItemAMGNGILD
NameAmgen Inc. Common StockGilead Sciences Inc.
Country/RegionUnited StatesUnited States
GICS SectorHealth CareHealth Care
GICS Industry GroupPharmaceuticals, Biotechnology & Life SciencesPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnologyBiotechnology
GICS Sub-IndustryBiotechnologyBiotechnology
Market Capitalization249.05 billion USD207.00 billion USD
CurrencyUSDUSD
ExchangeNasdaqNasdaq
Listing DateJune 17, 1983January 22, 1992
Security TypeCommon StockCommon Stock

Price Performance

Cumulative Growth

AMGN
GILD
GSPC
Loading price history…
Amgen (AMGN) vs. Gilead Sciences (GILD), with S&P 500 (GSPC) for reference: Growth of a $10,000 investment over the past five years. Adjusted for dividends and splits.

Trailing Returns

Loading price history…
Trailing total returns for Amgen (AMGN) and Gilead Sciences (GILD). Returns over one year are annualized.

Calendar-Year Returns

Loading price history…
Calendar-year total returns for Amgen (AMGN) and Gilead Sciences (GILD). Each bar is that year's total return, measured year-end to year-end.

Performance Metrics

Price performance metrics for Amgen (AMGN) and Gilead Sciences (GILD)
MetricAMGNGILD
Total Return (1Y)48.82%45.69%
Total Return (3Y, Annualized)24.31%35.30%
Total Return (5Y, Annualized)20.67%25.00%

Risk Profile

Drawdown History

AMGN
GILD
GSPC
Loading price history…
Amgen (AMGN) vs. Gilead Sciences (GILD), with S&P 500 (GSPC) for reference: Drawdown from the running peak over the past five years. Each line shows the decline from its prior peak; 0% marks a new high.

Return Distribution

Loading price history…
Distribution of monthly total returns for Amgen (AMGN) and Gilead Sciences (GILD). Each bar is the share of months whose return fell in that 5% bucket.

Risk Metrics

Risk profile metrics for Amgen (AMGN) and Gilead Sciences (GILD)
MetricAMGNGILD
Volatility (1Y, Annualized)29.12%27.57%
Beta (5Y)0.430.36
Max Drawdown (5Y)-24.86%-26.59%
Avg. Volume (3M)2.76M5.98M

Risk-Adjusted Performance

Risk-Return Positioning

Loading chart…
AMGN and GILD are plotted by 1-year volatility (risk) and 1-year return. The dashed Capital Allocation Line runs from the risk-free rate through the shared industry median.

Risk-Adjusted Metrics

Risk-adjusted metrics for Amgen (AMGN) and Gilead Sciences (GILD)
MetricAMGNGILD
Sharpe Ratio (1Y)1.531.50
Sortino Ratio (1Y)2.362.48

Profitability

ROE (TTM)

Gilead Sciences (GILD) reports a negative ROE of -22.45%; negative ROE can reflect losses or negative shareholders’ equity, so it is harder to read as capital efficiency. Meanwhile Amgen (AMGN) reports 78.35%, ranking against industry peers normally.

AMGN

Pharmaceuticals, Biotechnology & Life Sciences industry group

78.35%

Max
109.18%
AMGN
78.35%
Q3
6.23%
Median
-26.66%
Q1
-64.05%
Min
-167.77%

GILD

Pharmaceuticals, Biotechnology & Life Sciences industry group

-22.45%

Max
109.18%
Q3
6.23%
GILD
-22.45%
Median
-26.66%
Q1
-64.05%
Min
-167.77%
Loading chart…
Amgen (AMGN) vs. Gilead Sciences (GILD): A comparison of their ROE against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Net Margin (TTM)

Gilead Sciences (GILD) reports a negative net margin of -12.46%, usually indicating a net loss over the period. Meanwhile Amgen (AMGN) reports 24.14%, ranking against industry peers normally.

AMGN

Pharmaceuticals, Biotechnology & Life Sciences industry group

24.14%

AMGN
24.14%
Max
18.05%
Q3
4.78%
Median
0.00%
Q1
-4.14%
Min
-17.05%

GILD

Pharmaceuticals, Biotechnology & Life Sciences industry group

-12.46%

Max
18.05%
Q3
4.78%
Median
0.00%
Q1
-4.14%
GILD
-12.46%
Min
-17.05%
Loading chart…
Amgen (AMGN) vs. Gilead Sciences (GILD): A comparison of their net margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Operating Margin (TTM)

Both Amgen (AMGN) at 35.79% and Gilead Sciences (GILD) at 42.43% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.

AMGN

Pharmaceuticals, Biotechnology & Life Sciences industry group

35.79%

Max
83.12%
AMGN
35.79%
Q3
14.77%
Median
0.00%
Q1
-78.82%
Min
-207.40%

GILD

Pharmaceuticals, Biotechnology & Life Sciences industry group

42.43%

Max
83.12%
GILD
42.43%
Q3
14.77%
Median
0.00%
Q1
-78.82%
Min
-207.40%
Loading chart…
Amgen (AMGN) vs. Gilead Sciences (GILD): A comparison of their operating margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Profitability Metrics

Profitability metrics for Amgen (AMGN) and Gilead Sciences (GILD)
MetricAMGNGILD
ROE (TTM)78.35%-22.45%
ROA (TTM)8.91%13.47%
Net Margin (TTM)24.14%-12.46%
Operating Margin (TTM)35.79%42.43%
Gross Margin (TTM)72.47%79.95%

Growth

Revenue Growth

Both Amgen (AMGN) at 9.95% and Gilead Sciences (GILD) at 2.39% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.

Loading chart…
Amgen (AMGN) vs. Gilead Sciences (GILD): A comparison of their Revenue Growth across different time periods.

EPS Growth

Both companies show strong earnings momentum, but Gilead Sciences (GILD) at 1,684.21% is the standout with EPS growth above its industry range; Amgen (AMGN) at 88.23% also sits in the top quartile.

Loading chart…
Amgen (AMGN) vs. Gilead Sciences (GILD): A comparison of their EPS Growth across different time periods.

Growth Metrics

Growth metrics for Amgen (AMGN) and Gilead Sciences (GILD)
MetricAMGNGILD
Revenue Growth (YoY)9.95%2.39%
Revenue Growth (3Y CAGR)11.77%2.57%
EPS Growth (YoY)88.23%1,684.21%
EPS Growth (3Y CAGR)5.52%23.04%

Financial Strength

Current Ratio (MRQ)

Both Amgen (AMGN) at 1.48 and Gilead Sciences (GILD) at 1.38 run current ratio in the tighter-liquidity quartile of industry peers, leaving thinner cushions against current liabilities than typical competitors.

AMGN

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.48

Max
25.13
Q3
12.13
Median
5.52
Q1
2.47
AMGN
1.48
Min
0.10

GILD

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.38

Max
25.13
Q3
12.13
Median
5.52
Q1
2.47
GILD
1.38
Min
0.10
Loading chart…
Amgen (AMGN) vs. Gilead Sciences (GILD): A comparison of their current ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Debt / Equity (MRQ)

Debt sits unusually high against shareholders’ equity for both Amgen (AMGN) at 3.76 and Gilead Sciences (GILD) at 2.02 — each debt-to-equity ratio is above its industry benchmark range.

AMGN

Pharmaceuticals, Biotechnology & Life Sciences industry group

3.76

AMGN
3.76
Max
1.42
Q3
0.65
Median
0.15
Q1
0.02
Min
0.00

GILD

Pharmaceuticals, Biotechnology & Life Sciences industry group

2.02

GILD
2.02
Max
1.42
Q3
0.65
Median
0.15
Q1
0.02
Min
0.00
Loading chart…
Amgen (AMGN) vs. Gilead Sciences (GILD): A comparison of their debt-to-equity ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Financial Strength Metrics

Financial strength metrics for Amgen (AMGN) and Gilead Sciences (GILD)
MetricAMGNGILD
Current Ratio (MRQ)1.481.38
Debt / Equity (MRQ)3.762.02
Net Debt / EBITDA2.311.25

Dividends

Dividend Yield (TTM)

Both Amgen (AMGN) at 2.16% and Gilead Sciences (GILD) at 1.94% yield above their industries’ entire benchmark ranges — high enough that dividend safety, not income, becomes the first question.

AMGN

Pharmaceuticals, Biotechnology & Life Sciences industry group

2.16%

AMGN
2.16%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%

GILD

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.94%

GILD
1.94%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%
Loading chart…
Amgen (AMGN) vs. Gilead Sciences (GILD): A comparison of their dividend yield against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Payout Ratio (TTM)

Both Amgen (AMGN) at 57.62% and Gilead Sciences (GILD) at 43.46% pay out more of their earnings than any of their industry peers — the thinnest cover in their groups, so dividend headroom deserves attention.

AMGN

Pharmaceuticals, Biotechnology & Life Sciences industry group

57.62%

AMGN
57.62%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%

GILD

Pharmaceuticals, Biotechnology & Life Sciences industry group

43.46%

GILD
43.46%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%
Loading chart…
Amgen (AMGN) vs. Gilead Sciences (GILD): A comparison of their payout ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Metrics

Dividend metrics for Amgen (AMGN) and Gilead Sciences (GILD)
MetricAMGNGILD
Dividend Yield (TTM)2.16%1.94%
Dividend Payout Ratio (TTM)57.62%43.46%

Valuation

P/E Ratio (TTM)

An earnings multiple is available for just one side: Amgen (AMGN) trades at 26.69 times trailing earnings, ranked against its peers, while Gilead Sciences (GILD) has no P/E ratio this period.

AMGN

Pharmaceuticals, Biotechnology & Life Sciences industry group

26.69

Max
85.34
Q3
43.46
AMGN
26.69
Median
26.69
Q1
13.30
Min
0.07

GILD

Pharmaceuticals, Biotechnology & Life Sciences industry group

--

Max
85.34
Q3
43.46
Median
26.69
Q1
13.30
Min
0.07
GILD
--
Loading chart…
Amgen (AMGN) vs. Gilead Sciences (GILD): GILD does not report P/E ratio, so it has no value marker; AMGN is benchmarked against the Pharmaceuticals, Biotechnology & Life Sciences industry group.

P/S Ratio (TTM)

On P/S ratio, both Amgen (AMGN) at 6.40 and Gilead Sciences (GILD) at 6.68 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.

AMGN

Pharmaceuticals, Biotechnology & Life Sciences industry group

6.40

Max
58.18
Q3
25.77
Median
7.30
AMGN
6.40
Q1
3.01
Min
0.01

GILD

Pharmaceuticals, Biotechnology & Life Sciences industry group

6.68

Max
58.18
Q3
25.77
Median
7.30
GILD
6.68
Q1
3.01
Min
0.01
Loading chart…
Amgen (AMGN) vs. Gilead Sciences (GILD): A comparison of their P/S ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/B Ratio (MRQ)

Measured against book value, both Amgen (AMGN) at 17.35 and Gilead Sciences (GILD) at 15.88 look expensive — each P/B ratio sits above its industry’s benchmark range.

AMGN

Pharmaceuticals, Biotechnology & Life Sciences industry group

17.35

AMGN
17.35
Max
13.53
Q3
6.54
Median
3.25
Q1
1.69
Min
-5.59

GILD

Pharmaceuticals, Biotechnology & Life Sciences industry group

15.88

GILD
15.88
Max
13.53
Q3
6.54
Median
3.25
Q1
1.69
Min
-5.59
Loading chart…
Amgen (AMGN) vs. Gilead Sciences (GILD): A comparison of their P/B ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Valuation Metrics

Valuation metrics for Amgen (AMGN) and Gilead Sciences (GILD)
MetricAMGNGILD
P/E Ratio (TTM)26.69--
P/S Ratio (TTM)6.406.68
P/B Ratio (MRQ)17.3515.88
Free Cash Flow Yield (TTM)2.96%5.16%